HCPLive Network

Heart Failure Total Cost Estimated at $70 Billion by 2030

THURSDAY, April 25 (HealthDay News) -- The impact of heart failure is likely to increase, with more than eight million U.S. adults anticipated to have heart failure by 2030, at an estimated total cost of $70 billion, according to a study published online April 24 in Circulation: Heart Failure.

Paul A. Heidenreich, MD, from Stanford University, in California, and colleagues estimated the epidemiology and future costs of heart failure from 2012 to 2030, based on a model that assumes heart failure prevalence will remain constant and that the costs and technological innovation will continue to increase at the same rate.

The researchers projected that more than eight million people in the Unites States will have heart failure by 2030. The direct costs of medications are expected to increase from $21 billion in 2012 to $53 billion in 2030. The estimated total costs, including indirect costs, are expected to increase from $31 billion to $70 billion. Assuming all costs of cardiac care for patients with heart failure are attributable to heart failure, and not to comorbid conditions, the cost estimates projected for 2030 would be $160 billion in direct costs.

"Assuming continuation in present practice patterns, the cost of heart failure is projected to increase markedly over the next 18 years based on demographic changes in the population," the authors write. "The cost would be substantial, with each U.S. adult, on average, paying $244 annually by 2030 to care for the 10 million patients with heart failure."

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The immune system is the new focus of much work on traumatic brain injury (TBI). In a challenge to the paradigm that the blood brain barrier prevents harmful leukocytes from entering the brain, a Texas team tried to neutralize the impact of these cells. Peripheral lymphocytes are activated after TBI. They may then act as potential antigen presenting cells and get into the brain, causing cells there to degenerate.
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
Increasing use of hospice in the final days of ovarian cancer does not offset intensive end-of-life care in older women, according to a study published online Oct. 6 in the Journal of Clinical Oncology.
The CDC announces monitoring for all passengers from 3 Ebola-stricken nations, part of increased surveillance efforts as new Ebola czar Ron Klain starts firs day of work. Meanwhile, Bentley, the dog confined because his owner Dallas nurse Nina Pham has the virus, is cleared to go home. NBC medical editor Nancy Snyderman released from her Princeton, NJ home quarantine, and the NBC cameraman stricken with the disease is now Ebola-free.
More Reading